**Specifications Table**TableSubject area*Medicine*More specific subject area*Neurology, Immunology, Neuroimmunology*Type of data*Tables*How data was acquired*Real-time PCR, ABI PRISM*® *7000 System (Applied Biosystems, Life Technologies Corporation, USA), data statistical analysis (GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA,*[www.graphpad.com](http://www.graphpad.com){#ir0135}*)*Data format*Analyzed*Experimental factors*Peripheral blood mononuclear cells (PBMC) isolated by gradient centrifugation from whole blood of subjects with clinically isolated syndromes (CIS), and cultured for 48 h alone or with PHA 10 μg/ml. A sample of freshly isolated PBMC was used to isolate CD4+ T effector (Teff) and regulatory (Treg) cells by means of immunomagnetic sorting.*Experimental features*Real-time PCR analysis of mRNA levels of dopaminergic receptors, adrenoceptors and tyrosine hydroxylase mRNA levels, following total RNA extraction by PerfectPure™ RNA Cell & Tissue kit (5Prime, Milano, Italy), reverse transcription by a random primer and a high-capacity cDNA RT kit (Applied Biosystems, Life Technologies Corporation, USA), and cDNA amplification by TaqMan® Universal PCR Master Mix (Applied Biosystems), using the TaqMan Gene Expression Assay.*Data source location*Varese, Gallarate, Como (Italy)*Data accessibility*Data is within this article*

**Value of the data**•These data provide the profile of expression of dopaminergic receptors, adrenoceptors and tyrosine hydroxylase genes in circulating lymphocytes of subjects with clinically isolated syndromes (CIS).•The data are of value for further experiments on the mechanistic role of dopaminergic and adrenergic pathways in circulating lymphocytes during CIS and multiple sclerosis (MS).•The data give a basis for longitudinal, prospective clinical studies aimed at validating dopaminergic receptors and/or adrenoceptors gene expression in lymphocytes as early markers of CIS progressing to MS.

1. Data {#s0005}
=======

Enclosed are data regarding mRNA levels for dopaminergic receptors (DR), adrenoceptors (AR) and tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, found in peripheral blood mononuclear cells (PBMC) ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}) and in CD4+ T effector (Teff) cells ([Table 3](#t0015){ref-type="table"}) and regulatory (Treg) cells ([Table 4](#t0020){ref-type="table"}) from subjects with clinically isolated syndromes (CIS), which is a first, usually recovering, episode of neurological disturbance(s) suggestive of multiple sclerosis (MS). Each table provides a comparison between subjects who, after 12 months from CIS, did not progress or progressed to clinically established MS. For further information and discussion about the interpretation and implications of DR, AR and TH mRNA levels in lymphocytes of CIS subjects, please refer to the article [@bib1].

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. PBMC isolation and culture {#s0015}
-------------------------------

Cells were obtained from venous blood of CIS subjects enrolled at the Centre for research on Multiple Sclerosis, Ospedale S. Antonio Abate of Gallarate (VA) (Investigator in charge: Mauro Zaffaroni), at the Neurology Unit of the "Ospedale di Circolo e Fondazione Macchi", University of Insubria - School of Medicine of Varese (Investigator in charge: Giorgio Bono), and at the Neurological Department, Valduce Hospital, Como (Investigator in charge: Mario Guidotti). Inclusion and exclusion criteria for selection and enrollement of CIS subjects, as well as criteria to define conversion of CIS to MS are detailed elsewhere [@bib1]. Approval of the protocol was obtained from the Ethics Committee of the Ospedale S. Antonio Abate of Gallarate (VA), and all the participants provided a written informed consent.

PBMC were isolated from whole blood by using Ficoll--Paque Plus density gradient centrifugation, using standard procedures [@bib2]. PBMC were finally cultured in RPMI 1640/10% heath-inactivated fetal bovine serum, added with 2 mM glutamine and 100 U/ml penicillin/streptomycin, at the concentration of 1×10^6^ cells/ml, at 37 °C in a moist atmosphere of 5% CO~2~. Cells were cultured for 48 h, alone or in the presence of PHA 10 μg/ml, a concentration which was previously shown to be optimal to trigger mRNA expression of TH [@bib3]. PBMC were finally harvested and assayed for DR, AR and TH mRNA expression by means of real-time PCR.

2.2. Preparation of Teff and Treg {#s0020}
---------------------------------

Immunomagnetic sorting of Treg and Teff from freshly isolated PBMC was performed by using the Dynal CD4+CD25+ Treg Kit (Dynal, Oslo, Norway), as previously described [@bib4]. Treg and Teff were directly assayed for DR, AR and TH mRNA expression by means of real-time PCR.

2.3. Real-time PCR {#s0025}
------------------

Extraction of total RNA was performed with PerfectPure™ RNA Cell & Tissue kit (5Prime, Milano, Italy). RNA was then reverse-transcribed to cDNA using a random primer, high-capacity cDNA RT kit (Applied Biosystems, Life Technologies Corporation, USA), and finally amplified by *Ta*qMan® Universal PCR Master Mix (Applied Biosystems), using the *Taq*Man Gene Expression Assay ([Table 5](#t0025){ref-type="table"}). Assayed of cDNA was accomplished on an ABI PRISM® 7000 System (Applied Biosystems). Gene expression levels were finally expressed as 2^−*ΔCt*^ where *ΔCt=*\[*Ct* (sample)−*Ct* (housekeeping gene)\], and normalized to 18S cDNA, using the AB Prism 7000 SDS software™. Annealing temperature was 60 °C for all the genes.

2.4. Statistics {#s0030}
---------------

Data are reported as means±standard deviation (SD). The D׳Agostino & Pearson normality test was used to assess the distribution of values. The two-tailed Student׳s *t* test for unpaired data or the Mann--Whitney test for continuous variables were used to assess differences between groups. Calculations were performed using a commercial software (GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, [www.graphpad.com](http://www.graphpad.com){#ir0140}).
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###### 

Levels of DR, AR and TH mRNA in resting PBMC from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2^−*ΔCt*^×10^7^.

Table 1

  **Gene**                                  **CISnc**        **CISc**        **Ratio CISc/CISnc**   ***P***
  ----------------------------------------- ---------------- --------------- ---------------------- ---------
  TH                                        0.544±0.469      0.585±0.643     1.075                  0.878
  DRD2[a](#tbl1fna){ref-type="table-fn"}    0.062±0.010      0.083±0.035     1.336                  0.219
  DRD3                                      6.288±2.273      9.868±4.232     1.569                  0.041
  DRD5                                      81.073±134.865   46.128±42.210   0.569                  0.390
  ADRA1A                                    0.076±0.034      0.082±0.019     1.077                  0.618
  ADRA1B                                    0.991±0.702      1.418±0.806     1.431                  0.232
  ADRA1D                                    40.271±10.107    43.439±13.895   1.079                  0.583
  ADRA2A                                    0.075±0.046      0.116±0.070     1.559                  0.151
  ADRA2B                                    undetected       undetected      n/a                    n/a
  ADRA2C                                    0.055±0.023      0.053±0.033     0.961                  0.873
  ADRB1                                     0.554±0.329      0.342±0.180     0.617                  0.070
  ADRB2[b](#tbl1fnb){ref-type="table-fn"}   0.659±0.582      1.180±1.781     1.790                  0.438
  ADRB3                                     0.149±0.084      0.186±0.079     1.244                  0.329

Notes:

n/a=not applicable.

=levels of mRNA below detection limits in 3 CISnc and 3 CISc subjects;

=data from sample of one CISc subject excluded from the analysis due to assay failure.

###### 

Levels of DR, AR and TH mRNA in PHA-stimulated PBMC from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2^−*ΔCt*^×10^7^.

Table 2

  **Gene**                                   **CISnc**         **CISc**          **Ratio CISc/CISnc**   ***P***
  ------------------------------------------ ----------------- ----------------- ---------------------- ---------
  TH                                         17.349±19.878     21.587±23.140     1.244                  0.673
  DRD2                                       0.111±0.044       0.122±0.096       1.096                  0.773
  DRD3                                       212.251±102.955   227.008±146.229   1.070                  0.806
  DRD5                                       615.891±755.387   447.890±448.168   0.727                  0.527
  ADRA1A                                     0.176±0.034       0.270±0.116       1.540                  0.052
  ADRA1B                                     149.347±204.884   153.014±225.484   1.025                  0.971
  ADRA1D                                     212.433±152.730   199.297±132.607   0.938                  0.837
  ADRA2A                                     0.634±0.484       1.431±0.957       2.257                  0.043
  ADRA2B[a](#tbl2fna){ref-type="table-fn"}   0.034±0.012       0.051±0.007       1.493                  0.046
  ADRA2C                                     0.183±0.169       0.202±0.130       1.105                  0.771
  ADRB1                                      1.520±0.794       1.308±0.668       0.861                  0.519
  ADRB2[b](#tbl2fnb){ref-type="table-fn"}    6.156±2.782       8.788±4.242       1.428                  0.141
  ADRB3                                      0.602±0.369       0.659±0.295       1.095                  0.698

Notes:

=levels of mRNA below detection limits in 5 CISnc and 8 CISc subjects;

=data from sample of one CISc subject excluded from the analysis due to assay failure.

###### 

Levels of DR, AR and TH mRNA in Teff from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2^−*ΔCt*^×10^7^.

Table 3

  **Gene**                                   **CISnc**        **CISc**          **Ratio CISc/CISnc**   ***P***
  ------------------------------------------ ---------------- ----------------- ---------------------- ---------
  TH                                         0.932±0.667      1.514±1.680       1.625                  0.367
  DRD2[a](#tbl3fna){ref-type="table-fn"}     0.061±0.012      0.091±0.037       1.495                  0.083
  DRD3                                       71.274±40.127    160.645±224.222   2.254                  0.283
  DRD5                                       38.986±32.811    45.656±25.700     1.171                  0.617
  ADRA1A                                     0.104±0.027      0.136±0.038       1.303                  0.056
  ADRA1B                                     23.090±20.545    40.727±30.437     1.764                  0.170
  ADRA1D                                     121.840±68.792   155.881±73.368    1.279                  0.312
  ADRA2A                                     0.182±0.116      0.229±0.134       1.263                  0.421
  ADRA2B[a](#tbl3fna){ref-type="table-fn"}   undetected       undetected        n/a                    n/a
  ADRA2C                                     0.055±0.034      0.085±0.047       1.547                  0.138
  ADRB1                                      0.894±0.411      0.801±0.581       0.896                  0.700
  ADRB2                                      5.479±2.738      5.379±4.585       0.982                  0.957
  ADRB3                                      0.226±0.140      0.243±0.122       1.076                  0.797

Notes:

n/a=not applicable.

=levels of mRNA below detection limits in 2 CISnc and 3 CISc subjects.

###### 

Levels of DR, AR and TH mRNA in Treg from CIS subjects who, after 12 months from CIS, did not convert (CISnc) or converted (CISc) to clinically established MS. Levels of mRNA are expressed as 2^−*ΔCt*^×10^7^.

Table 4

  **Gene**                                   **CISnc**         **CISc**          **Ratio CISc/CISnc**   ***P***
  ------------------------------------------ ----------------- ----------------- ---------------------- ---------
  TH                                         6.239±5.575       6.029±5.332       0.966                  0.935
  DRD2[a](#tbl4fna){ref-type="table-fn"}     0.098±0.044       0.162±0.083       1.657                  0.090
  DRD3[b](#tbl4fnb){ref-type="table-fn"}     524.542±320.649   675.012±505.025   1.287                  0.470
  DRD5                                       179.094±96.190    271.145±87.095    1.514                  0.044
  ADRA1A                                     0.178±0.084       0.228±0.096       1.277                  0.260
  ADRA1B                                     539.118±634.164   685.947±919.180   1.272                  0.703
  ADRA1D                                     273.060±162.944   431.602±273.593   1.581                  0.164
  ADRA2A                                     0.533±0.401       0.708±0.576       1.329                  0.471
  ADRA2B[a](#tbl4fna){ref-type="table-fn"}   undetected        undetected        n/a                    n/a
  ADRA2C                                     0.147±0.152       0.168±0.098       1.139                  0.724
  ADRB1                                      2.299±2.183       1.284±0.734       0.558                  0.166
  ADRB2                                      13.974±9.163      15.322±9.322      1.096                  0.758
  ADRB3                                      0.402±0.228       0.470±0.240       1.170                  0.583

Notes:

n/a=not applicable.

=levels of mRNA below detection limits in 1 CISnc and 3 CISc subjects;

=data from sample of one CISc subject excluded from the analysis due to assay failure.

###### 

Real-Time PCR conditions.

Table 5

  **Gene**   **UniGene ID**   **Interrogated sequence***RefSeq/GenBank mRNA*   **Protein**                                  **Exon boundary**   **Assay location**   **Amplicon length**   **Efficiency** (%)
  ---------- ---------------- ------------------------------------------------ -------------------------------------------- ------------------- -------------------- --------------------- --------------------
  TH         Hs.435609        [NM_199292.2](ncbi-n:NM_199292.2){#ir0005}       [NP_954986.2](ncbi-p:NP_954986.2){#ir0010}   3--4                424--422             63                    94.5
  DRD2       Hs.73893         [NM_000795.3](ncbi-n:NM_000795.3){#ir0015}       [NP_000786.1](ncbi-p:NP_000786.1){#ir0020}   2--3                524                  64                    100.0
  DRD3       Hs.121478        [NM_033663.3](ncbi-n:NM_033663.3){#ir0025}       [NP_387512.3](ncbi-p:NP_387512.3){#ir0030}   3--4                809--725             73                    97.6
  DRD5       Hs.380681        [NM_000798.4](ncbi-n:NM_000798.4){#ir0035}       [NP_000789.1](ncbi-p:NP_000789.1){#ir0040}   1--1                1092--744            88                    110.2
  ADRA1A     Hs. 709175       [NM_033302.2](ncbi-n:NM_033302.2){#ir0045}       [NP_150645.2](ncbi-p:NP_150645.2){#ir0050}   1--2                1324                 112                   100.0
  ADRA1B     Hs. 368632       [NM_000679.3](ncbi-n:NM_000679.3){#ir0055}       [NP_000670.1](ncbi-p:NP_000670.1){#ir0060}   1--2                1126                 61                    100.0
  ADRA1D     Hs. 557          [NM_000678.3](ncbi-n:NM_000678.3){#ir0065}       [NP_000669.1](ncbi-p:NP_000669.1){#ir0070}   1--2                1166                 68                    100.1
  ADRA2A     Hs. 249159       [NM_000681.3](ncbi-n:NM_000681.3){#ir0075}       [NP_000672.3](ncbi-p:NP_000672.3){#ir0080}   1--1                1960                 116                   101.0
  ADRA2B     Hs. 247686       [NM_000682.5](ncbi-n:NM_000682.5){#ir0085}       [NP_000673.2](ncbi-p:NP_000673.2){#ir0090}   1--1                823                  117                   100.0
  ADRA2C     Hs. 123022       [NM_000683.3](ncbi-n:NM_000683.3){#ir0095}       [NP_000674.2](ncbi-p:NP_000674.2){#ir0100}   1--1                646                  93                    99.1
  ADRB1      Hs. 99913        [NM_000684.2](ncbi-n:NM_000684.2){#ir0105}       [NP_000675.1](ncbi-p:NP_000675.1){#ir0110}   1--1                863                  79                    99.0
  ADRB2      Hs. 2551         [NM_000024.5](ncbi-n:NM_000024.5){#ir0115}       [NP_000015.1](ncbi-p:NP_000015.1){#ir0120}   1--1                778                  65                    100.0
  ADRB3      Hs. 2549         [NM_000025.2](ncbi-n:NM_000025.2){#ir0125}       [NP_000016.1](ncbi-p:NP_000016.1){#ir0130}   1--2                1401                 65                    99.9
  18S rRNA   X03205.1         N.A.                                             N.A.                                         N.A.                N.A.                 187                   98.8
